PRO MEDICUS LIMITED — Annual Report 2007

Aug 27, 2007

Rule 4.2A

Appendix 4E Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited
ABN or equivalentcompany reference	Financial year ended('current period')	Financial year ended('previous period')
25 006 194 752	30 June 2007	30 June 2006
	2. Results for announcement to the market	2007
ASXListingRulesRef		A$'000

Ref
2.1	Revenue from continuous operations	13,035
	% change up/(down) of revenue from ordinary activities fromthe previous corresponding period.	Up11.9%
2.2	Profit/(Loss) after tax attributable to members	7,052
	% change up/(down) of Profit/(Loss) from ordinary activitiesafter tax attributable to members from the previouscorresponding period	Up15.3%
2.3	Net Profit/(Loss) for the period attributable to members	7,052
	% change up/(down) of Net Profit/(Loss) for the periodattributable to members from the previous correspondingperiod.	Up15.3%

2.4	Dividends (distributions)	Amount persecurity	Franked amountper security
	Franked dividend amount per security
	Final Dividend	3.00¢	3.00¢
	Special Final Dividend	1.00¢	1.00¢
	Interim dividend	2.50¢	2.50¢
	Special Interim Dividend	0.50¢	0.50¢
2.5	Record date for Final & Special dividends	20 September, 2007
	Payment date for Final & Special dividends	4 October, 2007

2.6 Operating Results for the Period

Pro Medicus reported an after tax profit of $7,052 million making this the most profitable year in Pro Medicus history. Revenue also rose to a record $13,035 million an increase of 11.9% on the previous year.

The company's Australian operations performed well over the past year with revenue increasing by approximately 3.4% from 9.1M to 9.4M. Promedicus.net, the company's e-health offering, continued its growth in both the number of doctors registered as well as transaction volumes with the network carrying 3.1 million transactions for the year, a 7.2% increase on the previous year.

The number of doctors registered to use promedicus.net increased from 22,000 doctors to 25,300 an increase of 15% compared to the same time last year, and the company intends to leverage its relationship with them to cross-sell its other products and services.

Building on the success of the first digital imaging installation at Lake Imaging, the company has now installed the technology at an increasing number of sites, covering private, large corporate and public radiology providers. Increased levels of market interest reinforce the company's confidence that the efficiency and clinical benefits the technology offers will inevitably drive the radiology industry towards a fully digital environment.

The past year has also seen the company continue to make significant inroads into overseas markets particularly the US and Canada with revenue from overseas operations increasing from $2.308 million to 3.092 million a 33.96% increase.

The North American market provided approximately 24% of the total revenue and Pro Medicus aims to continue to expand within this lucrative market by leveraging Agfa's substantial presence in the US and by extending its product offering.

Canada has also continued to provide ongoing opportunity for the company providing approximately 10.4% of the total revenue.

Throughout the year, the company continued its focus on higher margin software sales, e-health and services. Net margin as defined by profit before tax to revenue from operating activities increased from 75.8% in 2006 to 77.6% in 2007.

The Company is pleased to report a dividend return to shareholders of a total of 7.0 cents per share which is an increase of 1.5 cents over the previous period and represents the largest dividend payout in the company's history. This is made up of a final dividend of 3.00 cents plus a special dividend of 1.00 cent per share plus the interim dividend of 2.50 cents plus a special interim of 0.5 cents.

The directors are confident that the holdings of reserve cash after paying out both the second half and special dividends is sufficient to safeguard the development and expansion needs of the company as the business looks to increase its penetration of existing markets and new product development.

3.	Income Statement
	Please refer to the Income Statement in the attached Financial Statements.
4.	Balance Sheet
	Please refer to the Balance Sheet in the attached Financial Statements.
5.	Cash Flow Statement
	Please refer to the Cash Flow Statement in the attached Financial Statements.
6.	Details of Dividends
		2007$'000	2006$'000
	Final Dividend
	A Final Dividend of 3.00 cents (2006: 2.00) per share fullyfranked will be paid on 4 October 2007.	$3000.6	$2000
	A Special Dividend of 1.00 cents (2006: 1.00) per sharefully franked will be paid on 4 October 2007.	$1000.2	$1000
	Current Year Interim
	An interim dividend of 2.50 cents (2006: 2.00) per sharefully franked was paid on 4 April 2007.	$2500.5	$2000
	A Special Dividend of 0.50 cents (2006: 0.5) per sharefully franked was paid on 4 April 2007.	$500.1	$500
	No foreign sourced dividend or distribution is included in either the interim or finaldividends.
7.	Dividend or Distribution reinvestment plansThere are no dividend or distribution reinvestment plans in operation.
8.	Statement of Retained Earnings
	Please refer to Statement of Changes in equity in the attached Financial Statements.
9.	Net Tangible Assets per security	2007	2006
	Net Tangible Assets per security	0.12	$0.12
10.	Details of entities over which control has been gained or lost during theperiod
	There are no entities over which control has been gained or lost during the period.
11.	Associates and joint venture entities
	There are no associates or relevant joint ventures.
12.	Other significant information needed by an investor to make an informedassessment of the entity's financial performance and financial position.Please refer to section 2.6.
13.	Foreign Entity accounting standardsNot applicable.

14.	Commentary on results for the period.
	The earnings per security and the nature of any dilution aspects.
	Please refer to Note 6 of the attached Financial Statements.
	Returns to shareholders including distributions and buy backs.
	Please refer to Note 7 of the attached Financial Statements.
	Significant features of operating performance.
	Please refer to section 2.6.
	The results of segments that are significant to an understanding of the business.
	Please refer to Note 3 of the attached Financial Statements.
	Discussion of trends in performance.
	Please refer to section 2.6.
15.	Audit Statement
	This report is based on accounts to which one of the following applies.
	(Tick one)
	+The +Theaccountshavebeenaccounts have been subject to
	audited.review.
	+
	The +Theaccountsareintheaccounts have not yet been
	process of being audited oraudited or reviewed.
	subject to review.

Sign here: Date: 28 August 2007

Print name:	Sean Collins
	Company Secretary